Overview Dividends

(KNSA) Kiniksa Pharmaceuticals - Ratings and Ratios

Exchange: NASDAQ • Country: United Kingdom • Currency: USD • Type: Common Stock • ISIN: BMG5269C1010

ARCALYST, Vixarelimab, KPL-387

EPS (Earnings per Share)

EPS (Earnings per Share) of KNSA over the last years for every Quarter: "2020-09": -0.66, "2020-12": -0.79, "2021-03": -0.72, "2021-06": -0.61, "2021-09": -0.44, "2021-12": -0.53, "2022-03": -0.36, "2022-06": -0.29, "2022-09": 3.18, "2022-12": 0.06, "2023-03": -0.18, "2023-06": 0.21, "2023-09": -0.2, "2023-12": 0.35, "2024-03": -0.25, "2024-06": -0.06, "2024-09": -0.18, "2024-12": -0.12, "2025-03": 0.11, "2025-06": 0.23, "2025-09": 0.23,
EPS Growth (3y CAGR): 63.01%
EPS Trend (3y Corr): 23.6%
Last SUE: -0.38σ
Qual. Beats: 0

Revenue

Revenue of KNSA over the last years for every Quarter: 2020-09: 0, 2020-12: 0, 2021-03: 0, 2021-06: 7.704, 2021-09: 12.095, 2021-12: 18.745, 2022-03: 32.189, 2022-06: 26.972, 2022-09: 99.135, 2022-12: 61.884, 2023-03: 48.345, 2023-06: 71.473, 2023-09: 67.046, 2023-12: 83.395, 2024-03: 79.858, 2024-06: 108.631, 2024-09: 112.214, 2024-12: 122.536, 2025-03: 137.785, 2025-06: 156.797, 2025-09: 180.855,
Revenue Growth (3y CAGR): 47.69%
Revenue Trend (3y Corr): 97.1%
Last SUE: 2.09σ
Qual. Beats: 2
Risk via 10d forecast
Volatility 43.5%
Value at Risk 5%th 64.9%
Relative Tail Risk -9.23%
Reward TTM
Sharpe Ratio 1.70
Alpha 84.64
Character TTM
Hurst Exponent 0.450
Beta 0.510
Beta Downside 0.827
Drawdowns 3y
Max DD 38.77%
Mean DD 13.51%
Median DD 12.39%

Description: KNSA Kiniksa Pharmaceuticals November 10, 2025

Kiniksa Pharmaceuticals International plc (NASDAQ: KNSA) is a London-based biopharma focused on novel therapies for unmet cardiovascular needs. Its lead product, ARCALYST (dual IL-1α/β inhibitor), targets recurrent pericarditis, while its pipeline includes Vixarelimab for prurigo nodularis and KPL-387, a monthly sub-Q IL-1R1 antibody designed to simplify treatment of advanced recurrent pericarditis. The company also maintains a pre-clinical Fc-engineered antibody, KPL-116, and rebranded from Kiniksa Pharmaceuticals Ltd in June 2024.

As of the most recent 10-Q (Q2 2024), KNSA reported ~ $78 million of cash and equivalents, giving it roughly 12 months of runway at its current burn rate of $6–7 million per quarter. The firm’s partnership with Roche for ARCALYST’s U.S. commercialization provides a non-dilutive revenue stream and validates the IL-1 pathway’s therapeutic relevance. In the broader biotech sector, global spending on cardiovascular drug R&D is projected to grow at a CAGR of ~ 7 % through 2028, driven by an aging population and increasing prevalence of inflammatory cardiac disorders.

For a deeper quantitative assessment of KNSA’s risk-adjusted upside, the ValueRay platform offers a transparent, data-first model worth a look.

KNSA Stock Overview

Market Cap in USD 3,129m
Sub-Industry Biotechnology
IPO / Inception 2018-05-24
Return 12m vs S&P 500 74.9%
Analyst Rating 4.67 of 5

KNSA Dividends

Currently no dividends paid

KNSA Growth Ratios

Metric Value
CAGR 3y 38.50%
CAGR/Max DD Calmar Ratio 0.99
CAGR/Mean DD Pain Ratio 2.85
Current Volume 455.6k
Average Volume 402.1k

Piotroski VR‑10 (Strict, 0-10) 5.5

Net Income (35.9m TTM) > 0 and > 6% of Revenue (6% = 35.9m TTM)
FCFTA 0.14 (>2.0%) and ΔFCFTA 12.28pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 58.86% (prev 56.07%; Δ 2.79pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA 0.14 (>3.0%) and CFO 102.9m > Net Income 35.9m (YES >=105%, WARN >=100%)
Net Debt (-165.1m) to EBITDA (45.1m) ratio: -3.66 <= 3.0 (WARN <= 3.5)
Current Ratio 3.85 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (78.0m) change vs 12m ago 8.78% (target <= -2.0% for YES)
Gross Margin 52.77% (prev 60.90%; Δ -8.14pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 94.34% (prev 69.17%; Δ 25.18pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -8.70 (EBITDA TTM 45.1m / Interest Expense TTM -5.01m) >= 6 (WARN >= 3)

Altman Z'' -1.30

(A) 0.49 = (Total Current Assets 475.5m - Total Current Liabilities 123.6m) / Total Assets 712.3m
(B) -0.67 = Retained Earnings (Balance) -476.3m / Total Assets 712.3m
(C) 0.07 = EBIT TTM 43.6m / Avg Total Assets 633.8m
(D) -2.69 = Book Value of Equity -476.5m / Total Liabilities 176.9m
Total Rating: -1.30 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 68.46

1. Piotroski 5.50pt
2. FCF Yield 3.65%
3. FCF Margin 17.01%
4. Debt/Equity 0.02
5. Debt/Ebitda -3.66
6. ROIC - WACC (= -1.77)%
7. RoE 7.46%
8. Rev. Trend 97.11%
9. EPS Trend 23.64%

What is the price of KNSA shares?

As of November 21, 2025, the stock is trading at USD 41.49 with a total of 455,571 shares traded.
Over the past week, the price has changed by +2.98%, over one month by +6.41%, over three months by +24.93% and over the past year by +95.62%.

Is KNSA a buy, sell or hold?

Kiniksa Pharmaceuticals has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy KNSA.
  • Strong Buy: 4
  • Buy: 2
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the KNSA price?

Issuer Target Up/Down from current
Wallstreet Target Price 54 30.2%
Analysts Target Price 54 30.2%
ValueRay Target Price 57.6 38.8%

KNSA Fundamental Data Overview November 20, 2025

Market Cap USD = 3.13b (3.13b USD * 1.0 USD.USD)
P/E Trailing = 91.7333
P/E Forward = 30.6748
P/S = 5.2324
P/B = 5.8611
Beta = 0.025
Revenue TTM = 598.0m USD
EBIT TTM = 43.6m USD
EBITDA TTM = 45.1m USD
Long Term Debt = 9.72m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 2.70m USD (from shortTermDebt, last quarter)
Debt = 9.72m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -165.1m USD (from netDebt column, last quarter)
Enterprise Value = 2.79b USD (3.13b + Debt 9.72m - CCE 352.1m)
Interest Coverage Ratio = -8.70 (Ebit TTM 43.6m / Interest Expense TTM -5.01m)
FCF Yield = 3.65% (FCF TTM 101.7m / Enterprise Value 2.79b)
FCF Margin = 17.01% (FCF TTM 101.7m / Revenue TTM 598.0m)
Net Margin = 6.01% (Net Income TTM 35.9m / Revenue TTM 598.0m)
Gross Margin = 52.77% ((Revenue TTM 598.0m - Cost of Revenue TTM 282.4m) / Revenue TTM)
Gross Margin QoQ = 53.78% (prev 54.71%)
Tobins Q-Ratio = 3.91 (Enterprise Value 2.79b / Total Assets 712.3m)
Interest Expense / Debt = 18.85% (Interest Expense 1.83m / Debt 9.72m)
Taxrate = 32.12% (8.72m / 27.2m)
NOPAT = 29.6m (EBIT 43.6m * (1 - 32.12%))
Current Ratio = 3.85 (Total Current Assets 475.5m / Total Current Liabilities 123.6m)
Debt / Equity = 0.02 (Debt 9.72m / totalStockholderEquity, last quarter 535.4m)
Debt / EBITDA = -3.66 (Net Debt -165.1m / EBITDA 45.1m)
Debt / FCF = -1.62 (Net Debt -165.1m / FCF TTM 101.7m)
Total Stockholder Equity = 481.6m (last 4 quarters mean from totalStockholderEquity)
RoA = 5.04% (Net Income 35.9m / Total Assets 712.3m)
RoE = 7.46% (Net Income TTM 35.9m / Total Stockholder Equity 481.6m)
RoCE = 8.88% (EBIT 43.6m / Capital Employed (Equity 481.6m + L.T.Debt 9.72m))
RoIC = 6.15% (NOPAT 29.6m / Invested Capital 481.6m)
WACC = 7.92% (E(3.13b)/V(3.14b) * Re(7.90%) + D(9.72m)/V(3.14b) * Rd(18.85%) * (1-Tc(0.32)))
Discount Rate = 7.90% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 33.33 | Cagr: 3.63%
[DCF Debug] Terminal Value 79.01% ; FCFE base≈65.5m ; Y1≈68.9m ; Y5≈80.9m
Fair Price DCF = 31.40 (DCF Value 1.42b / Shares Outstanding 45.2m; 5y FCF grow 5.66% → 3.0% )
EPS Correlation: 23.64 | EPS CAGR: 63.01% | SUE: -0.38 | # QB: 0
Revenue Correlation: 97.11 | Revenue CAGR: 47.69% | SUE: 2.09 | # QB: 2

Additional Sources for KNSA Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle